1. A prognostic model for platinum‐doublet as second‐line chemotherapy in advanced non‐small‐cell lung cancer patients. (19th March 2016) Authors: Mo, Hongnan; Hao, Xuezhi; Liu, Yutao; Wang, Lin; Hu, Xingsheng; Xu, Jianping; Yang, Sheng; Xing, Puyuan; Shi, Youwu; Jia, Bo; Wang, Yan; Li, Junling; Wang, Hongyu; Wang, Ziping; Sun, Yan; Shi, Yuankai Journal: Cancer medicine Issue: Volume 5:Number 6(2016:Jun.) Page Start: 1116 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A Prospective Study of Apatinib in Patients with Extensive‐Stage Small Cell Lung Cancer After Failure of Two or More Lines of Chemotherapy. (6th April 2020) Authors: Liu, Yutao; Hu, Xingsheng; Jiang, Jun; Yang, Lin; Zhou, Shengyu; Liu, Peng; Li, Junling; Wang, Yan; Hao, Xuezhi; Shi, Yuankai Journal: Oncologist Issue: Volume 25:Number 5(2020) Page Start: e833 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Issue 21 (21st September 2021) Authors: Li, Teng; Wang, Shouzheng; Ying, Jianming; Wang, Yan; Hu, Xingsheng; Hao, Xuezhi; Xu, Ziyi; Xing, Puyuan; Li, Junling Journal: Thoracic cancer Issue: Volume 12:Issue 21(2021) Page Start: 2924 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Clinical effect of pemetrexed as the first‐line treatment in Chinese patients with advanced anaplastic lymphoma kinase‐positive non‐small cell lung cancer. Issue 4 (11th May 2016) Authors: Ma, Di; Hao, Xuezhi; Wang, Yan; Xing, Puyuan; Li, Junling Journal: Thoracic cancer Issue: Volume 7:Issue 4(2016) Page Start: 452 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Clinical features and outcomes of ALK rearranged non‐small cell lung cancer with primary resistance to crizotinib. Issue 5 (16th April 2019) Authors: Ma, Di; Zhang, Yan; Xing, Puyuan; Hao, Xuezhi; Wang, Mengzhao; Wang, Yan; Shan, Li; Xin, Tao; Liang, Hongge; Du, Yang; Zhang, Zhaohui; Liang, Li; Li, Junling Journal: Thoracic cancer Issue: Volume 10:Issue 5(2019) Page Start: 1213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Clinical outcome, long‐term survival and tolerability of sequential therapy of first‐line crizotinib followed by alectinib in advanced ALK+NSCLC: A multicenter retrospective analysis in China. Issue 1 (1st December 2021) Authors: Zou, Zihua; Hao, Xuezhi; Zhang, Cuiying; Li, Haojing; Dong, Guilan; Peng, Yumei; Ma, Kewei; Guo, Ye; Shan, Li; Zhang, Yan; Liang, Li; Gu, Yangchun; Xing, Puyuan; Li, Junling Journal: Thoracic cancer Issue: Volume 13:Issue 1(2022) Page Start: 107 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Clinicopathologic characteristics and outcome of patients with different EGFR mutations. Issue 3 (11th October 2018) Authors: Zhou, Shengyu; Hu, Xingsheng; Wang, Yan; Li, Junling; Zhou, Liqiang; Hao, Xuezhi; Liu, Yutao; Shi, Yuankai Journal: Asia-Pacific journal of clinical oncology Issue: Volume 15:Issue 3(2019) Page Start: 166 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma. Issue 19 (6th September 2021) Authors: Wang, Shouzheng; Xie, Tongji; Hao, Xuezhi; Wang, Yan; Hu, Xingsheng; Wang, Lin; Li, Yan; Li, Junling; Xing, Puyuan Journal: Thoracic cancer Issue: Volume 12:Issue 19(2021) Page Start: 2585 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Concurrent chemotherapy and first‐generation epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) with or without an antiangiogenic agent as first‐line treatment in advanced lung adenocarcinoma harboring an EGFR mutation. Issue 16 (28th June 2021) Authors: Xu, Ziyi; Hao, Xuezhi; Lin, Lin; Li, Junling; Xing, Puyuan Journal: Thoracic cancer Issue: Volume 12:Issue 16(2021) Page Start: 2233 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer. Issue 10 (8th August 2019) Authors: Xing, Puyuan; Han, Xiaohong; Wang, Sha; Liu, Yutao; Yang, Sheng; Hao, Xuezhi; Wang, Yan; Liu, Peng; Li, Junling; Wang, Lin; Chang, Lianpeng; Guan, Yanfang; Zhang, Zhishang; Wu, Di; Yao, Jiarui; Yi, Xin; Shi, Yuankai Journal: Journal of cellular and molecular medicine Issue: Volume 23:Issue 10(2019) Page Start: 6812 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗